![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Bone and Renal Safety Are Improved in Chronic HBV Patients 1 Year After Switching to Tenofovir Alafenamide From Tenofovir Disoproxil Fumarate
|
|
|
Reported by Jules Levin
AASLD Nov 9-13 2018 SF
![1230181](../images%20/123018/123018-1/1230181.gif)
![1230182](../images%20/123018/123018-1/1230182.gif)
![1230183](../images%20/123018/123018-1/1230183.gif)
![1230184](../images%20/123018/123018-1/1230184.gif)
![1230185](../images%20/123018/123018-1/1230185.gif)
![1230186](../images%20/123018/123018-1/1230186.gif)
![1230187](../images%20/123018/123018-1/1230187.gif)
![1230188](../images%20/123018/123018-1/1230188.gif)
References: 1. Babusis D, et al. Mol Pharmaceutics 2013;10:459-66; 2. Lee WA, et al. Antimicrob Agents Chemother 2005;49:1898-906; 3. Murakami E, et al. Antimicrob Agents Chemother 2015;59:3563-9; 4. Agarwal K, et al. J Hepatol 2015;62:533-40; 5. Sax P, et al. Lancet 2015;385:2606-15; 6. Agarwal K, et al. J Hepatol 2018;68:672-81; 7. Pan C, et al. AASLD 2017, poster 904.
Acknowledgments: We extend our thanks to the patients, their families, and all participating investigators. These studies were funded by Gilead Sciences, Inc.
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|